Watchdog endorses use of Tysabri for severe MS

Biogen Idec and Elan won an important endorsement for Tysabri with a recommendation from Britain's cost-effectiveness watchdog--the National Institute for Health and Clinical Excellence--that the drug be made available to patients with the most severe form of the disease. Tysabri has been making a steady comeback since the therapy was derailed in early '05 after patients taking the drug developed a rare brain disease. Regulators ushered it back onto the market after adding some restrictive guidelines on its use after a large contingent of MS patients demanded access to the therapy.

- check out the release
- read the report from the Irish Times

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.